慢性肾脏病和终末期肾病患者的血脂异常
Dyslipidemia in patients with chronic and end-stage kidney disease.
作者信息
Omran Jad, Al-Dadah Ashraf, Dellsperger Kevin C
出版信息
Cardiorenal Med. 2013 Oct;3(3):165-177. doi: 10.1159/000351985. Epub 2013 Jul 13.
Abstract
In this review, we discuss the physiology, diagnosis and treatment of dyslipidemia in patients with chronic and end-stage renal disease. The recent important clinical trials in patients with chronic kidney disease and dyslipidemia are reviewed. Because of the lack of evidence in treating lipid abnormalities in this specific patient population, we propose that future studies should focus on the pathophysiological mechanisms and treatment of dyslipidemia in this special patient population.
摘要
在本综述中，我们讨论了慢性和终末期肾病患者血脂异常的生理学、诊断和治疗。对近期慢性肾病合并血脂异常患者的重要临床试验进行了综述。由于在这一特定患者群体中治疗血脂异常缺乏证据，我们建议未来的研究应聚焦于这一特殊患者群体血脂异常的病理生理机制和治疗。
相似文献
1
Dyslipidemia in patients with chronic and end-stage kidney disease.
Cardiorenal Med. 2013 Oct;3(3):165-177. doi: 10.1159/000351985. Epub 2013 Jul 13.
2
Statins for treatment of dyslipidemia in chronic kidney disease.
Perit Dial Int. 2006 Sep-Oct;26(5):523-39.
3
The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
Clin Nephrol. 2006 Nov;66(5):336-47. doi: 10.5414/cnp66336.
4
Dyslipidemia in patients with chronic kidney disease: etiology and management.
Int J Nephrol Renovasc Dis. 2017 Feb 7;10:35-45. doi: 10.2147/IJNRD.S101808. eCollection 2017.
5
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Cell Signal. 2019 Mar;55:53-64. doi: 10.1016/j.cellsig.2018.12.001. Epub 2018 Dec 12.
6
Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease.
Curr Opin Nephrol Hypertens. 2002 Mar;11(2):141-7. doi: 10.1097/00041552-200203000-00003.
7
Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
Pharmacotherapy. 2010 Aug;30(8):823-9. doi: 10.1592/phco.30.8.823.
8
Lipid abnormalities associated with end-stage renal disease.
Semin Dial. 2006 Jan-Feb;19(1):32-40. doi: 10.1111/j.1525-139X.2006.00117.x.
9
Dyslipidemia in patients with chronic kidney disease.
Rev Endocr Metab Disord. 2017 Mar;18(1):29-40. doi: 10.1007/s11154-016-9402-z.
10
Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.
Pediatr Nephrol. 2015 Dec;30(12):2073-84. doi: 10.1007/s00467-015-3075-9. Epub 2015 Mar 24.
引用本文的文献
1
Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome.
Cardiovasc Drugs Ther. 2024 Nov 16. doi: 10.1007/s10557-024-07649-y.
2
Does metabolic syndrome increase contrast-induced nephropathy in patients with normal renal function?
J Res Med Sci. 2024 Jan 30;29:5. doi: 10.4103/jrms.jrms_136_21. eCollection 2024.
3
Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment.
Redox Biol. 2023 Aug;64:102762. doi: 10.1016/j.redox.2023.102762. Epub 2023 Jun 2.
4
Lipid status association with 25-hydroxy vitamin D: Cross sectional study of end stage renal disease patients.
J Med Biochem. 2020 Sep 2;39(3):309-317. doi: 10.2478/jomb-2019-0032.
5
Dyslipidemia and Intraperitoneal Inflammation Axis in Peritoneal Dialysis Patients: A Cross-Sectional Pilot Study.
Kidney Dis (Basel). 2020 Jan;6(1):35-42. doi: 10.1159/000503632. Epub 2019 Nov 6.
6
Association between Dyslipidemia and Peritoneal Dialysis Technique Survival.
Open Access Maced J Med Sci. 2019 Jul 25;7(15):2467-2473. doi: 10.3889/oamjms.2019.664. eCollection 2019 Aug 15.
7
The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.
Int Urol Nephrol. 2019 Dec;51(12):2235-2242. doi: 10.1007/s11255-019-02319-7. Epub 2019 Oct 22.
8
Metabolic Syndrome and the Iodine-Dose/Creatinine Clearance Ratio as Determinants of Contrast-Induced Acute Kidney Injury.
Cardiorenal Med. 2018;8(3):217-227. doi: 10.1159/000488374. Epub 2018 Jun 15.
9
Effects of dyslipidaemia on monocyte production and function in cardiovascular disease.
Nat Rev Cardiol. 2017 Jul;14(7):387-400. doi: 10.1038/nrcardio.2017.34. Epub 2017 Mar 16.
10
Dyslipidemia in patients with chronic kidney disease: etiology and management.
Int J Nephrol Renovasc Dis. 2017 Feb 7;10:35-45. doi: 10.2147/IJNRD.S101808. eCollection 2017.
本文引用的文献
1
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
BMJ. 2013 Mar 18;346:f880. doi: 10.1136/bmj.f880.
2
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
Eur Heart J. 2013 May;34(17):1279-91. doi: 10.1093/eurheartj/eht055. Epub 2013 Feb 26.
3
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.
4
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
N Engl J Med. 2011 Dec 15;365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15.
5
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.
6
Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization.
Am J Cardiol. 2011 Jun 15;107(12):1710-7. doi: 10.1016/j.amjcard.2011.02.336. Epub 2011 Apr 18.
7
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
Clin J Am Soc Nephrol. 2011 Jun;6(6):1316-25. doi: 10.2215/CJN.09121010. Epub 2011 Apr 14.
8
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Nature. 2010 Apr 29;464(7293):1357-61. doi: 10.1038/nature08938.
9
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30.
10
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
Zotero 插件